Can Fite Biopharma

Can Fite Biopharma Current Assets

The Current Assets of Can Fite Biopharma (CANF.TA) as of Oct 17, 2026 is 9.37 M USD. In the previous year, Current Assets was 10.00 M USD — a change of -6.32% (lower).

Current Assets

9.37 MUSD

YoY

-6.32%

Last updated:

Current Assets of Can Fite Biopharma is 2025 9.37 M USD. Current Assets of Can Fite Biopharma was 2024 10.00 M USD. It decreases by -6.32% lower compared to the previous year.

The Can Fite Biopharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
3.97 M USD
Jan 1, 2019
6.51 M USD
Jan 1, 2020
9.38 M USD
Jan 1, 2021
20.02 M USD
Jan 1, 2022
9.11 M USD
Jan 1, 2023
9.91 M USD
Jan 1, 2024
10.00 M USD
Jan 1, 2025
9.37 M USD
The Can Fite Biopharma Current Assets history
YEARCurrent AssetsYoY
9.37 MUSD-6.32%
10.00 MUSD+0.93%
9.91 MUSD+8.76%
9.11 MUSD-54.50%
20.02 MUSD+113.39%
9.38 MUSD+44.18%
6.51 MUSD+63.90%
3.97 MUSD+18.44%
3.35 MUSD-66.84%
10.11 MUSD-42.19%
17.48 MUSD+380.04%
3.64 MUSD+67.10%
2.18 MUSD+221.80%
677,294.76USD-58.96%
1.65 MUSD+837.80%
175,985.96USD-21.39%
223,873.60USD-52.52%
471,497.95USD-55.35%
1.06 MUSD+44.67%
730,000.00USD+170.28%
270,087.76USD+309.22%
66,000.00USD-67.00%
200,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Can Fite Biopharma Stock analysis

What does Can Fite Biopharma do? Can-Fite Biopharma Ltd. is an Israeli company specializing in the development of drugs for inflammatory diseases and cancer. It was founded in 1994 by Prof. Pnina Fishman and is headquartered in Petach Tikva, Israel. The company initially focused on studying the function of adenosine receptors in central nervous system diseases, but later expanded to develop drugs for inflammatory diseases and cancer. Can-Fite went public in 2007 and has been able to finance its research projects through investors and partnerships. The company's business model revolves around developing an innovative portfolio of drugs for immune system disorders and cancer by targeting adenosine receptors. It aims to expand its drug pipeline to successfully treat a wide range of diseases. Can-Fite's drug pipeline is divided into different areas, including inflammatory diseases, cancer, and ophthalmology. The company has already brought several drugs to market or is in the clinical testing phase, including CF101 for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer, and Piclidenoson for autoimmune diseases. Overall, Can-Fite Biopharma Ltd. is a promising company focused on developing innovative drugs for inflammatory diseases and cancer. Can Fite Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Can Fite Biopharma stock

Current Assets of Can Fite Biopharma is 9.37 M USD in 2025.

Current Assets of Can Fite Biopharma changed from 10.00 M USD to 9.37 M USD, representing a -6.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Can Fite Biopharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Can Fite Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Can Fite Biopharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Can Fite Biopharma